´ëÇÑ°£ÇÐȸ APASL 2022 (DAY 1) : 2022-03-30±³À°ÀÏÀÚ : 2022-03-30
±³À°Àå¼Ò : (¿Â, ¿ÀÇÁ¶óÀÎ º´Çà) ¿ÀÇÁ¶óÀÎ Àå¼Ò: ¼¿ï ÄÚ¿¢½º
±³À°ÁÖÁ¦ :
(¿Â-¿ÀÇÁº´Çà) APASL 2022 (DAY 1)ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
´ã´çÀÚ : APASL 2022 Áغñ»ç¹«±¹
¿¬¶ôó : 02-707-0091
À̸ÞÀÏ :
apasl2022@insession.co.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 15 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 800,000¿ø
ºñ°í Category Early Bird Rate Regular Rate Onsite Rate December 31(Fri), 2021 February 20(Sun), 2022 Off-line Virtual Off-line Virtual Off-line VirtualAPASL Member USD 300 USD200 USD400 USD300 USD 500 USD 400Non APASL Member USD 500 USD 300 USD 600 USD 400 USD 700 USD 500Trainee/Resident/Nurse USD 200 USD 100 USD 300 USD 200 USD 400 USD 300Accompanying Person USD 150 - USD 200 - USD 300 -Industry Partner USD 600 USD 600 USD 700 USD 700 USD 800 USD 800 / *»çÀüµî·Ï2022³â 2¿ù 20ÀÏ(ÀÏ)±îÁö [ÇöÀå] Àü¹®ÀÇ 30¸¸¿ø, ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç 15¸¸¿ø, µ¿¹ÝÀÚ 15¸¸¿ø, Industry Partner 70¸¸¿ø [¿Â¶óÀÎ] Àü¹®ÀÇ 25¸¸¿ø, ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç 12¸¸¿ø, Industry Partner 70¸¸¿ø, *ÇöÀåµî·Ï [ÇöÀå] Àü¹®ÀÇ 35¸¸¿ø, ÀüÀÓÀÇ,Àü°øÀÇ,°£È£»ç 18¸¸¿ø, µ¿¹ÝÀÚ 18¸¸¿ø, Industry Partner 80¸¸¿ø [¿Â¶óÀÎ] Àü¹®ÀÇ 30¸¸¿ø, ÀüÀÓÀÇ/Àü°øÀÇ/°£È£»ç 15¸¸¿ø, Industry Partner 80¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-30 101, 1F 10:30~10:50 Introduction to single-cell RNA sequencing (including nuclear RNA-sequecing) Jong-Eun Park(Korea Advanced Institute of Science and Technology)
±³À°½Ã°£ 03-30 101, 1F 10:50~11:20 Study of the human liver cell atlas Thomas Baumert(INSERM, University of Strasbourg)
±³À°½Ã°£ 03-30 101, 1F 11:20~11:50 Single-cell RNA sequencing in HCC Zemin Zhang(School of Life Sciences, Peking University)
Åä·Ð 03-30 101, 1F 11:50~12:00 Discussion ()
±³À°½Ã°£ 03-30 101, 1F 13:30~13:50 Overview of the liver immune system Eui-Cheol Shin(Korea Advanced Institute of Science and Technology)
±³À°½Ã°£ 03-30 101, 1F 13:50~14:10 Characteristics of liver NK cells Cliona O(School of Medicine, Trinity Biomedical Science Institute, Trinity College Dublin)
±³À°½Ã°£ 03-30 101, 1F 14:10~14:30 T cell responses against HBV Masanori Isogawa(Research Center for Drug and Vaccine Development, NIID)
±³À°½Ã°£ 03-30 101, 1F 14:30~14:50 T-cell engineering for the treatment of liver diseases Antonio Bertoletti(Duke-NUS Medical School)
Åä·Ð 03-30 101, 1F 14:50~15:00 Discussion ()
±³À°½Ã°£ 03-30 101, 1F 15:30~15:50 Update in HBV research Peter Revill(Royal Melbourne Hospital)
±³À°½Ã°£ 03-30 101, 1F 15:50~16:10 Recent progress in HBV entry Koichi Watashi(National Institute of Infectious Diseases)
±³À°½Ã°£ 03-30 101, 1F 16:10~16:30 Development of capsid inhibitors Sung-Gyoo Park(College of Pharmacy Seoul National University)
±³À°½Ã°£ 03-30 101, 1F 16:30~16:50 HBV integration and HCC Shiou-Hwei Yeh(National Taiwan University Hospital)
Åä·Ð 03-30 101, 1F 16:50~17:00 Discussion ()
±³À°½Ã°£ 03-30 102, 1F 10:30~10:50 Emerging role of artificial intelligence and big data in liver diseases Wai-Kay Seto(The University of Hong Kong)
±³À°½Ã°£ 03-30 102, 1F 10:50~11:10 Clinical research with big data in hepatology: promises and challenges Terry Cheuk-Fung Yip(Faculty of Medicine, The Chinese University of Hong Kong)
±³À°½Ã°£ 03-30 102, 1F 11:10~11:30 Deep learning using electronic medical records in liver diseases Tung-Hung Su(National Taiwan University Hospital)
±³À°½Ã°£ 03-30 102, 1F 11:30~11:50 Machine-learning approach for novel predictive models Ryosuke Tateishi(Graduate School of Medicine, The University of Tokyo)
Åä·Ð 03-30 102, 1F 11:50~12:00 Discussion ()
±³À°½Ã°£ 03-30 102, 1F 13:30~13:50 Human genome and liver diseases Masashi Mizokami(National Center for Global Health and Medicine)
±³À°½Ã°£ 03-30 102, 1F 13:50~14:10 Genetic and genomic methods to study risk of HBV and HCV infection and patient outcome Hwai-I Yang(Genomic Research Center, Academia Sinica)
±³À°½Ã°£ 03-30 102, 1F 14:10~14:30 Continuous molecular spectrum of liver cancers associated with radio-genomic and histologic features Hyun Goo Woo(Ajou University School of Medicine)
±³À°½Ã°£ 03-30 102, 1F 14:30~14:50 How to translate genomic understandings into clinical practice Jean-Charles Nault(Jean Verdier Hospital)
Åä·Ð 03-30 102, 1F 14:50~15:00 Discussion ()
±³À°½Ã°£ 03-30 102, 1F 15:30~15:50 How to write a good paper? Seung Up Kim(Yonsei University College of Medicine)
±³À°½Ã°£ 03-30 102, 1F 15:50~16:10 Tips for selecting right journal for submission Jia-Horng Kao(National Taiwan University College of Medicine)
±³À°½Ã°£ 03-30 102, 1F 16:10~16:30 Tips for impressing the editor Jean-Charles Nault(Jean Verdier Hospital)
±³À°½Ã°£ 03-30 102, 1F 16:30~16:50 Reasons why some papers are accepted or rejected? Paolo Angeli(University-Teaching Hospital of Padova)
Åä·Ð 03-30 102, 1F 16:50~17:00 Discussion ()
±³À°½Ã°£ 03-30 201+202+203, 2F 09:00~09:20 APASL 2022 PG course: Future trends in hepatology Jeong Won Jang(College of Medicine, The Catholic University of Korea)
±³À°½Ã°£ 03-30 201+202+203, 2F 09:20~09:40 Personalized treatment of viral hepatitis Teerha Piratvisuth(Songklanagarind Hospital, Prince of Songkla University)
±³À°½Ã°£ 03-30 201+202+203, 2F 09:40~10:00 Genetics and epigenetics in non-alcoholic fatty liver disease Won Kim(Seoul National University College of Medicine)
±³À°½Ã°£ 03-30 201+202+203, 2F 10:00~10:20 Translating omics data into biomarker discovery for liver cancer Irene O. L. Ng(The University of Hong Kong)
Åä·Ð 03-30 201+202+203, 2F 10:20~10:30 Discussion ()
±³À°½Ã°£ 03-30 201+202+203, 2F 10:30~10:50 NAFLD versus lean NAFLD or MAFLD Vincent Wong(Faculty of Medicine, The Chinese University of Hong Kong)
±³À°½Ã°£ 03-30 201+202+203, 2F 10:50~11:10 Targeting the gut-liver-brain connection Jasmohan S. Bajaj(Virginia Commonwealth University School of Medicine)
±³À°½Ã°£ 03-30 201+202+203, 2F 11:10~11:30 Innovative strategies for a cure of hepatitis B Seng Gee Lim(National University Health System)
±³À°½Ã°£ 03-30 201+202+203, 2F 11:30~11:50 Immuno-oncology in liver cancer: A change of paradigm Maria Reig(Hospital Clinic, University of Barcelona)
Åä·Ð 03-30 201+202+203, 2F 11:50~12:00 Discussion ()
±³À°½Ã°£ 03-30 201+202+203, 2F 13:30~13:50 New therapeutic targets in AIH, PBC, and PSC Atsushi Tanaka(Teikyo University School of Medicine)
±³À°½Ã°£ 03-30 201+202+203, 2F 13:50~14:10 Intestinal immune-microbiome interactions in alcoholic hepatitis Ki Tae Suk(Hallym University College of Medicine)
±³À°½Ã°£ 03-30 201+202+203, 2F 14:10~14:30 Immuno-microenvironment in NASH-associated HCC Amany Zekry(St George Hospital)
±³À°½Ã°£ 03-30 201+202+203, 2F 14:30~14:50 Immune tolerance and rejection in liver transplantation Jong Young Choi(College of Medicine, The Catholic University of Korea)
Åä·Ð 03-30 201+202+203, 2F 14:50~15:00 Discussion ()
±³À°½Ã°£ 03-30 201+202+203, 2F 15:30~15:50 Coagulopathy in cirrhosis: Balancing between bleeding and thrombotic state Ashok Choudhury(Institute of Liver and Biliary Sciences)
±³À°½Ã°£ 03-30 201+202+203, 2F 15:50~16:10 Pulmonary complications of cirrhosis Diana A Payawal(Fatima University Medical Center)
±³À°½Ã°£ 03-30 201+202+203, 2F 16:10~16:30 Beta adrenergic blockade in cirrhosis: Do good or harm? Dao Viet Hang(Hanoi Medical University)
±³À°½Ã°£ 03-30 201+202+203, 2F 16:30~16:50 Managing acute-on-chronic liver failure to successful recovery or transplant Rajiv Jalan(University College London Medical School, Royal Free Hospital)
Åä·Ð 03-30 201+202+203, 2F 16:50~17:00 Discussion ()